M. Chang

Pharmacokinetic/pharmacodynamic drug–drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs

J. Ferry, E. Schuck, P. Boyd, 2018, British journal of clinical pharmacology.

ELENBECESTAT, A NOVEL ORAL BACE INHIBITOR, HAS NO CLINICALLY MEANINGFUL EFFECT ON QTC INTERVAL UP TO A SUPRATHERAPEUTIC DOSE OF 200 MG

J. Ferry, B. Albala, B. Darpo, 2017, Alzheimer's & Dementia.

ELENBECESTAT PHARMACOKINETIC DRUG-DRUG INTERACTIONS INDICATED NO DOSAGE ADJUSTMENTS REQUIRED FOR MOST CONCOMITANT TREATMENTS

J. Ferry, B. Albala, R. Lai, 2017, Alzheimer's & Dementia.

Safety, pharmacokinetics, and pharmacodynamics in first-in-human study of a novel compound E6742, a Toll-like receptor 7 and 8 antagonist

R. Lai, S. Ishizaka, M. Matijević, 2018 .

Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel γ‐secretase modulator, E2212, in healthy human subjects

J. Ferry, E. Schuck, Yanke Yu, 2014, Journal of clinical pharmacology.